Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Prostatic Neoplasms 1Pancreatic Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Carcinoid Tumor 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1fluorodopa F 18 1cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × lutetium Lu 177 dotatate × 30 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡